A comparison of L-ascorbic acid and L-ascorbyl 6-palmitate utilization in Guinea Pigs and humans

Polysaccharide/gelatin blend films as carriers of ascorbyl palmitate - A comparative study

The comparative study was performed in order to assess the most suitable matrix polymer for ascorbyl palmitate (AP). The antioxidant (1 and 2% w/w) was loaded into the 75/25 blend films based on polysaccharides (gum Arabic (GAR), octenyl succinic anhydride modified starch (OSA), water soluble soy polysaccharides (WSSP)) and gelatin (GEL). The AP was present in the films both in the form of longitudinal crystals and microglobules. Because of amphiphilic character, the AP had the moisturizing action on the films; however, its addition reduced film solubility in water. AP did not affect the water vapor permeability and tensile strength of the OSA-based carrier. The Makoid-Banakar with T_lag model was suitable for the efficient simulation of AP release from the films. The OSA-based system offered the fastest release of AP and, consequently, had the best initial antiradical activity. The 1%AP-added GAR75/GEL25 film provided the most extended release of antioxidant capacity.

Opinion on the re‐evaluation of ascorbyl palmitate (E 304i) as a food additive in foods for infants below 16 weeks of age and the follow‐up of its re‐evaluation as a food additive for uses in foods for all population groups

Ascorbyl palmitate (E 304(i)) was re‐evaluated in 2015 by the former EFSA Panel on Food Additives and Nutrient sources added to Food (ANS). As a follow‐up to this assessment, the Panel on Food Additives and Flavourings (FAF) was requested to assess the safety of ascorbyl palmitate (E 304(i)) for its uses as food additive in food for infants below 16 weeks of age belonging to food categories 13.1.1 (Infant formulae) and 13.1.5.1 (Dietary foods for infants for special medical purposes and special formulae for infants) and as carry over in line with Annex III, Part 5 Section B to Regulation (EC) No 1333/2008. In addition, the FAF Panel was requested to address the issues already identified during the re‐evaluation of the food additive when used in food for the general population. The process involved the publication of a call for data to allow the interested business operators to provide the requested information to complete the risk assessment. On the basis of the data submitted by interested business operators and the considerations from the Panel, a revision of the existing EU specifications for ascorbyl palmitate (E 304 (i)) has been recommended. Based on in vitro data, the FAF Panel assumed that ascorbyl palmitate fully hydrolyses pre‐systemically to ascorbic acid and palmitate. The Panel concluded that the intake of both metabolites, at the MPLs for ascorbyl palmitate as a food additive in infant formula belonging to FC 13.1.1 or in food for special medical purposes belonging to FC 13.1.5.1, does not raise health concerns.

Tissue carnitine fluxes in vitamin C depleted-repleted guinea pigs

The biosynthesis of carnitine requires vitamin C as a cofactor for two separate hydroxylation steps. The majority of body carnitine (approximately 98%) is located in muscle and less than 0.5% is present in plasma. We examined the physiologic dynamics of plasma free carnitine and muscle total acid-soluble carnitine in vitamin C-depleted guinea pigs repleted with increasing amounts of vitamin C. Animals were fed a vitamin C-deficient diet for 3 weeks at which time symptoms of scurvy were evident. Animals were repleted with increasing doses of vitamin C, from 0.5 to 10.0 mg vitamin C/100 g body weight daily. Muscle total acid-soluble carnitine concentrations tended to correlate directly with plasma vitamin C (r = 0.41, P = 0.087) during the repletion phase of the study. Conversely, plasma free carnitine was inversely related to liver vitamin C (r = -0.54, P = 0.020) and to muscle total acid-soluble carnitine (r = -0.56, P = 0.015). Mean plasma free carnitine values fell 30% over the course of vitamin C repletion (P > 0.05) and mean muscle total acid-soluble carnitine rose by 30% (P > 0.05). These data suggest that elevated plasma free carnitine may indicate a low to marginal vitamin C status.